CLINICAL EVALUATION OF THE INSULIN RESISTANCE SYNDROME IN HYPERTENSIVE PATIENTS WITH NORMAL BODY WEIGHT

Objective. To evaluate the effect of insulin resistance on arterial hypertension and target organ damage  in patients with normal body weight. design and methods. The study involved 95 patients with arterial hypertension 1–2 degree (essential hypertension stage I–II) with normal body weight (body mass index 18,5– 24,9 kg/m 2) aged 30–50 years. The examination included fasting blood glucose, immunoreactive insulin, the index of insulin resistance — QUICKI factor, as well as lipids, serum uric acid and microalbuminuria. In addition, patients underwent ambulatory blood pressure monitoring, duplex scanning of neck vessels, echocardiography, endothelial function assessment. Results. The rate of insulin resistance-hyperinsulinaemia syndrome was 36 % in the studied group of hypertensive patients with normal body weight. Hypertensive patients with insulin resistance had higher average daily systolic blood pressure, higher rate and more severe target organ damage (left ventricular hypertrophy, endothelial dysfunction, intima media thickness). Among metabolic disorders, dyslipidemia was predominant, in particular, hypertriglyceridemia, as well as increased total cholesterol and LDL-cholesterol, and decrease in HDL-cholesterol. conclusions. Insulin resistance and hyperinsulinaemia syndrome is registered  in 36 % of hypertensive patients with normal body weight. They are characterized by high rate of hypertension and more severe target organ damage, and metabolic disorders (mainly hypertriglyceridemia).

hypertension, insulin resistance, hyperinsulinaemia, metabolic syndrome, insulin

1. Moller D, Flier J. Insulin resistance — mechanisms, syndromes, and implications. N Engl J Med. 1991;325(13): 938–48.

2. Nestler JE. Assessment of insulin resistance. Sci. Med. 1994;1:58–67.

3. Алмазов В. А., Благосклонная Я. В., Шляхто Е. В., Красильникова Е. И., Жукова А. В. Синдром исулинорезистентности. Артериальная гипертензия. 1997;3(1):7–17. [Almazov AV., Blagosklonnaya Ya. V., Shlyakhto EV., Krasilnikova EI., Zhukova AV. Insulin resistance syndrome. Arterial’naya Gipertenziya = Arterial Hypertension. 1997;3(1):7–17. In Russian].

4. Зимин Ю. В. Происхождение, диагностическая концепция и клиническое значение синдрома инсулинорезистентности или метаболического синдрома Х. Кардиология. 1998; 6:71–81. [Zimin Yu. V. Origin, diagnostic concept, and clinical value of the syndrome of insulin resistance or metabolic syndrome X. Kardiologiya. 1998;6:71–81. In Russian].

5. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L et al. Insulin resistance in essential hypertension. N. Engl. J. Med. 1987;317(6):350–357.

6. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes. 1998;47(10):1643–1649.

7. Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595–1607.

8. Matsushita M, Tsuchiya N, Nakayama T, Ohashi J, Shibue T, Shiota M et al. Allele typing of human TNFA 5'-flanking region using polymerase chain reaction-preferential homoduplex formation assay (PCR-PHFA): linkage disequilibrium with HLA class I and class II genes in Japanese. Tissue Antigens. 1999;54(5):478–484.

9. Rasmussen H, Zawalick KC., Ganesan S, Calle R, Zawalich WS. Physiology and pathophysiology of insulin secretion. Diabetes Care. 1990;13:655–666.

10. Hirata T, Higashiyama A, Kubota Y, Nishimura K, Sugiyama D, Kadota A et al. HOMA-IR values are associated with glycemic control in Japanese subjects without diabetes or obesity: The KOBE Study. J Epidemiology. 2015; 25(6): 407–414.

11. Шестакова М. В., Брескина О. Ю. Инсулинорезистентность: патофизиология, клинические проявления, подходы к лечению. Consilium medicum. 2002;10:523–527. [Shestakova MV, Breskina OY. Insulin resistance: pathophysiology, clinical manifestations, treatment approaches. Consilium medicum. 2002;10:523–527. In Russian].

12. Capaldo B, Lembo G, Napoli R, Rendina V, Albano G, Saccàet L et al. Skeletal muscle is a primary site of insulin resistance in essential hypertension. Metabolism. 1991;40 (12):1320–1322.

13. Nataly A, Santoro D, Palombo C, Cerri M, Ghione S, Ferranniniet E. Impared insulin action on skeletal muscle metabolism in essential hypertension. Hypertension. 1991;17 (2):170–178.

14. Landsberg L, Aronne LJ, Beilin LJ, Burke V, Igel LI, Lloyd-Jones D et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment. A position paper of The Obesity Society and the American Society of Hypertension. J Clin Hypertens (Greenwich). 2013;15(1):14–33.

15. Woerdeman J, Meijer RI, Eringa EC, Hoekstra T, Smulders YM., Serné EH. Insulin sensitivity determines effects of insulin and meal ingestion on systemic vascular resistance in healthy subjects. Microcirculation. 2016; 23(1):62–8.

16. Reaven GM. Role of insulin resistence in human disease: an expanded definition. Annual review of Medicine. 1993;44 (1):121–131.

17. Ferrari P, Weidmann P. Insulin, insulin sensitivity and hypertension. J Hypertens. 1990;8(6):491–500.

18. Juhlin-Dannfeld A, Frisk-Holmberg F, Karlsson J, Tesch P. Central and peripheral circulation in relation to musclefiber composition in normo- and hypertensive man. Clin Sci. 1979;56 (4):335–340.

19. Harrison DG. Endothelial function and oxidant stress. Clin. Cardial. 1997; 20(11 Suppl 2): II-11–17.

20. Ievskaia E, Sokolova L, Vavilova T, Savinova E. Effects of insulin resistance at lipid profile in Hypertensive patients with normal and overweight. Anitschkow Days Symposium of the International Atherosclerosis Society June 2–4, 2016; 229.